HER3 status by immunohistochemistry is correlated with poor prognosis in hormone receptor-negative breast cancer patients

HER3 Is Required for HER2-Induced Preneoplastic Changes to the Breast Epithelium and Tumor Formation

(2012) D. B. Vaught et al.   CANCER RESEARCH

A functional comparison between the HER2high/HER3 and the HER2low/HER3 dimers on heregulin-β1-induced MMP-1 and MMP-9 expression in breast cancer cells

(2012) Sangmin Kim et al.   EXPERIMENTAL AND MOLECULAR MEDICINE

ErbB3 Ablation Impairs PI3K/Akt-Dependent Mammary Tumorigenesis

(2011) R. S. Cook et al.   CANCER RESEARCH

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

(2011) Luca Gianni et al.   LANCET ONCOLOGY

Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase

(2011) J. T. Garrett et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

HER-3 Overexpression Is Prognostic of Reduced Breast Cancer Survival

(2010) Connie G. Chiu et al.   ANNALS OF SURGERY

Epidermal Growth Factor Receptor in Triple-Negative and Basal-Like Breast Cancer

(2010) Monika L. Burness et al.   CANCER JOURNAL

The HER3/ErbB3 receptor: A promising target in cancer drug therapy

(2010) C. Desbois-Mouthon   GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE

Triple-negative breast cancer: disease entity or title of convenience?

(2010) Lisa Carey et al.   Nature Reviews Clinical Oncology

EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab

(2009) S. Gori et al.   ANNALS OF ONCOLOGY

Quantitative multiplexed analysis of ErbB family coexpression for primary breast cancer prognosis in a large retrospective cohort

(2009) Jennifer M. Giltnane et al.   CANCER

The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine

(2009) J. S. Ross et al.   ONCOLOGIST

Invasive ductal carcinoma of the breast with the “triple-negative” phenotype: prognostic implications of EGFR immunoreactivity

(2008) Giuseppe Viale et al.   BREAST CANCER RESEARCH AND TREATMENT

The ERBB3 receptor in cancer and cancer gene therapy

(2008) G Sithanandam et al.   CANCER GENE THERAPY

A Central Role for HER3 in HER2-Amplified Breast Cancer: Implications for Targeted Therapy

(2008) S. T. Lee-Hoeflich et al.   CANCER RESEARCH

Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor-Activating Mutations

(2008) S. Yano et al.   CANCER RESEARCH

The Role of ErbB3 and its Binding Partners in Breast Cancer Progression and Resistance to Hormone and Tyrosine Kinase Directed Therapies

(2008) Anne W. Hamburger   JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA